Merck’s Keytruda Drives 50% of Pharma Sales as LM-299 Bispecific Enters Pipeline
Merck & Co.’s Keytruda accounts for around 50% of the company’s pharmaceutical sales, underscoring its leadership in immuno-oncology. In 2024 Merck secured a global license for LM-299, an investigational PD-1/VEGF bispecific antibody, as part of a broader oncology pipeline expansion.
1. Keytruda Market Dominance
Keytruda remains Merck’s flagship immuno-oncology therapy, contributing roughly half of the company’s pharmaceutical revenues through approvals across multiple cancer indications and sustained global demand.
2. LM-299 Bispecific License
In 2024 Merck obtained an exclusive global license from LaNova Biologics to develop, manufacture and commercialize LM-299, a novel bispecific antibody targeting PD-1 and VEGF designed to enhance anti-tumor efficacy.
3. Diversified Oncology Pipeline
Beyond Keytruda and LM-299, Merck is building a broad oncology portfolio that includes additional bispecifics, antibody-drug conjugates, small molecules and other immunotherapies to mitigate future revenue declines and drive long-term growth.